Who are OBIZUR's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Coagulation Factor VIII, Afstyla®, Xyntha, Recombinant Human Coagulation FVIII, Kogenate (BAY 14-2222), Efmoroctocog Alfa Injection [Eloctate].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/obizur.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

OBIZUR — Competitive Intelligence Brief

OBIZUR (OBIZUR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant coagulation factor VIII. Area: Hematology.

marketed Recombinant coagulation factor VIII Coagulation factor VIII Hematology Biologic Live · refreshed every 30 min

Target snapshot

OBIZUR (OBIZUR) — Baxalta now part of Shire. OBIZUR is a recombinant human Factor VIII that replaces deficient or dysfunctional Factor VIII to restore blood clotting ability in patients with hemophilia A.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
OBIZUR TARGET	OBIZUR	Baxalta now part of Shire	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Coagulation Factor VIII	Coagulation Factor VIII	Beijing Children's Hospital	marketed	Coagulation factor replacement	Coagulation Factor VIII (antihemophilic factor)
Afstyla®	Afstyla®	CSL Behring	marketed	Recombinant clotting factor VIII	Factor VIII (coagulation factor VIII)
Xyntha	xyntha	Pfizer	marketed	Recombinant protein therapy	Coagulation factor VIII
Recombinant Human Coagulation FVIII	Recombinant Human Coagulation FVIII	Sinocelltech Ltd.	marketed	Coagulation factor replacement therapy	Coagulation Factor VIII
Kogenate (BAY 14-2222)	Kogenate (BAY 14-2222)	Bayer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Efmoroctocog Alfa Injection [Eloctate]	Efmoroctocog Alfa Injection [Eloctate]	The League of Clinical Research, Russia	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII (intrinsic tenase complex)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant coagulation factor VIII class)

Baxalta now part of Shire · 2 drugs in this class
Bayer · 2 drugs in this class
Pfizer · 2 drugs in this class
The League of Clinical Research, Russia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OBIZUR — Competitive Intelligence Brief. https://druglandscape.com/ci/obizur. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab